Study schema of the IMPACT study. PFS is defined as the shortest time to first disease progression (determined using RECIST v1.1 or mRECIST) or death from any cause from the date of randomization. ORR is defined as the proportion of patients in whom the best overall response is either CR or PR from the date of initiation of induction therapy to the date of discontinuation of protocol treatment or the date of first observed progression or death, whichever occurs first. DOR is defined as the time from the date of the first confirmed response (the date of first documented CR or PR status) to the date of the first confirmed disease progression or death, whichever occurs first, after transition to the randomized cohort. Time to CR is defined as the time from randomization to the first occurrence of CR (determined using RECIST v1.1). ABC-conversion, atezolizumab plus bevacizumab followed by curative conversion; Atezo, atezolizumab; Bev, bevacizumab; BCLC-A, Barcelona Clinic Liver Cancer stage A (early stage); BCLC-B, Barcelona Clinic Liver Cancer stage B (intermediate stage); BCLC-C, Barcelona Clinic Liver Cancer (advanced stage); CR, complete response; DOR, duration of response; EHS, extrahepatic spread; MVI, macroscopic vascular invasion; NE, not evaluable; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; Q3W, every 3 weeks; R, randomization; (m)RECIST v1.1, (modified) Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease; TACE, transcatheter arterial chemoembolization; uHCC, unresectable hepatocellular carcinoma; Vp3-4, right, left, or main portal vein invasion
